You seem to be using an outdated version of Internet Explorer. Please note that this site does not support this browser version (a href="http://windows.microsoft.com/de-de/windows/end-support-help">as does Microsoft). You may experience design inconsistencies and error messages. We are sorry for any inconveniences.

News

Haniel invests in High-Tech Gründerfonds

1. June 2017
Complementing investments in venture capital funds as part of digital initiative Haniel, a German family-equity company, has invested in High-Tech Gründerfonds III (HTGF III). With HTGF III, up to 40 technology companies are expected to receive financial support with a target fund volume of €300 million per year. In addition to its financial involvement, the fund offers technology companies the More …

BÜFA fosters innovative tech start-ups

Oldenburg-based chemicals company takes stake in High-Tech Gründerfonds “I am delighted that BÜFA GmbH & Co. KG has decided to invest in High-Tech Gründerfonds. With your support, we intend to continue the success enjoyed by High-Tech Gründerfonds, a development that benefits Germany as a hub of business,” German cabinet minister Sigmar Gabriel wrote in an official letter to BÜFA, thanking More …

WISE Srl raises EUR 6.5 million for clinical validation of novel neuroelectrodes for brain monitoring and spinal cord stimulation

25. May 2017
Minimally invasive, highly conformable, foldable and stretchable electrodes for growing Neuromonitoring and Neuromodulation markets being developed WISE Srl, a medical device company developing next-generation implantable neuromodulation leads announces today the closing of a EUR 6.5 million series B financing round, led by Principia SGR, an Italian Venture Capital firm. Existing investors Atlante Ventures, High-Tech Gründerfonds, F3F and Antares joined the More …

High-Tech Gründerfonds (HTGF) invests in Reutlingen-based SIGNATOPE GmbH – Safe medications thanks to new test procedures

24. May 2017
High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection of possible side effects during the drug development process. Thereby, the need for animal testing More …

TolerogenixX secures seed funding and completes Phase I clinical trial

23. May 2017
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. In a Phase I clinical trial, the technique was successfully employed during kidney transplants. Patients who received transplants became tolerant of the donated organ. As a seed More …

Cardior Pharmaceuticals raises €15 million to develop first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and heart failure

11. May 2017
Cardior Pharmaceuticals, a spin-off from Hannover Medical School (MHH), today announced the completion of a €15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (with its new BioMedInvest III Fund) and High-Tech Gründerfonds (HTGF). Cardior is pioneering its proprietary RNA technology to revolutionize predicting and treating heart failure. More …

NUMAFERM revolutionizes peptide production and receives seed financing

The Dusseldorf university spin-off NUMAFERM specializes in the biotechnical production of peptides and is able, through its newly developed platform technology, to dramatically reduce costs for this raw material. For the further technological development and an accelerated market entry, NUMAFERM GmbH is now receiving funding in the seven-digit range. High-Tech Gründerfonds (HTGF), Qiagen co-founders and European Business Angels Prof. Detlev More …

KSK Diagnostics GmbH gains Innovationsstarter Fonds Hamburg and High-Tech Gründerfonds (HTGF) as partners to finance the development of molecular point-of-care diagnostic tests

24. April 2017
KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the time before therapy is started. A financing round has now been completed with Innovationsstarter Fonds Hamburg and High-Tech Gründerfonds in order to accelerate the development of the product and its More …

Symetis and Boston Scientific reach USD 435 million purchase agreement

7. April 2017
Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions Symetis’ IPO launched on Euronext Paris and very well received by the More …

Dräger acquires majority stake in Hamburg-based start-up bentekk

3. April 2017
Dräger Safety AG & Co. KGaA has acquired a 51 percent stake in bentekk GmbH from seed investors High-Tech Gründerfonds (HTGF) and Innovationsstarter Fonds Hamburg (IFH). This latest acquisition sees Dräger extend its expertise in the area of mobile gas measurement even further. bentekk, based in the south of Hamburg, specializes in developing innovative gas measurement devices for industrial applications. bentekk’s More …